# EDGAR Filing Document

**Accession Number:** 0001869105
**File Stem:** 0001193125-26-126590
**Filing Date:** 2026-3
**Character Count:** 8420
**Document Hash:** d53867944fb608250cda7001fe9fc095
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-126590.hdr.sgml**: 20260326

**ACCESSION NUMBER**: 0001193125-26-126590

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20260324

**FILED AS OF DATE**: 20260326

**DATE AS OF CHANGE**: 20260326

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Lebowitz Peter F
- **CENTRAL INDEX KEY:** 0002121402

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41955
- **FILM NUMBER:** 26799324

**MAIL ADDRESS:**
- **STREET 1:** 256 E. GRAND AVE., SUITE 104
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BridgeBio Oncology Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001869105
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 256 E. GRAND AVENUE, SUITE 104
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
- **BUSINESS PHONE:** 857 702 0377

**MAIL ADDRESS:**
- **STREET 1:** 256 E. GRAND AVENUE, SUITE 104
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Helix Acquisition Corp. II
- **DATE OF NAME CHANGE:** 20210623

## Ex-24.Poa

LIMITED POWER OF ATTORNEY

The undersigned hereby constitutes and appoints each of Eli Wallace,

Uneek Mehra, and Aaron Chan, signing singly, and with full power of

substitution, the undersigned's true and lawful attorney-in-fact to:

(1) execute for and on behalf of the undersigned, in the undersigned's

capacity as an officer, director, and/or securityholder of BridgeBio

Oncology Therapeutics, Inc., a Delaware corporation (the "Company"),

from time to time the following U.S. Securities and Exchange

Commission ("SEC") forms: (i) Form 3, Initial Statement of

Beneficial Ownership of Securities, including any attached

documents; (ii) Form 4, Statement of Changes in Beneficial Ownership

of Securities, including any attached documents; (iii) Form 5,

Annual Statement of Beneficial Ownership of Securities in accordance

with Section 16(a) of the Securities Exchange Act of 1934, as

amended, and the rules thereunder, including any attached

documents; (iv) Schedules 13D and 13G; and (v) amendments of each

thereof, in accordance with the Securities Exchange Act of 1934, as

amended, and the rules thereunder, including any attached documents;

(2) do and perform any and all acts for and on behalf of the undersigned

which may be necessary or desirable to complete and execute any such

Form 3, 4 or 5, Schedule 13D or 13G, or any amendment(s) thereto and

timely file such form(s) with the SEC and any securities exchange,

national association or similar authority; and

(3) take any other action of any type whatsoever in connection with the

foregoing which, in the opinion of such attorney-in-fact, may be of

benefit to, in the best interest of, or legally required by, the

undersigned, it being understood that the documents executed by such

attorney-in-fact on behalf of the undersigned pursuant to this Power

of Attorney shall be in such form and shall contain such terms and

conditions as such attorney-in-fact may approve in such

attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact, acting

singly, full power and authority to do and perform any and every act and

thing whatsoever requisite, necessary or proper to be done in the

exercise of any of the rights and powers herein granted, as fully to all

intents and purposes as the undersigned might or could do if personally

present, with full power of substitution or revocation, hereby ratifying

and confirming all that such attorney-in-fact, or such

attorney-in-fact's substitute or substitutes, shall lawfully do or cause

to be done by virtue of this power of attorney and the rights and powers

herein granted. The undersigned acknowledges that the foregoing

attorneys-in-fact, in serving in such capacity at the request of the

undersigned, are not assuming, nor is the Company assuming, any of the

undersigned's responsibilities to comply with Section 16 or Regulation

13D-G of the Securities Exchange Act of 1934, as amended. The

undersigned hereby agrees to indemnify the attorneys-in-fact and the

Company from and against any demand, damage, loss, cost or expense

arising from any false or misleading information provided by the

undersigned to the attorneys-in-fact.

This Power of Attorney shall remain in full force and effect until the

undersigned is no longer required to file such forms with respect to the

undersigned's holdings of and transactions in securities issued by the

Company, unless earlier revoked by the undersigned in a signed writing

delivered to the foregoing attorneys-in-fact. This Power of Attorney

supersedes any prior power of attorney in connection with the

undersigned's capacity as an officer and/or director of the Company.

------

This Power of Attorney shall expire as to any individual

attorney-in-fact if such attorney-in-fact ceases to be an employee of

the Company.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to

be executed as of March 24, 2026.

/s/ Peter Lebowitz

Signature

Peter Lebowitz

Print Name

------

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Lebowitz Peter F<br><sub>(Last) (First) (Middle)</sub><br>BRIDGEBIO ONCOLOGY THERAPEUTICS, INC.<br>256 EAST GRAND AVENUE, SUITE 104<br><sub>(Street)</sub><br>SOUTH SAN FRANCISCO, CA 94080<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>BridgeBio Oncology Therapeutics, Inc. [ BBOT ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2026-03-24 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director   [ ] 10% Owner<br>[ ] Officer (give title below)   [ ] Other (specify below)<br>_ _ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
|  |  |  |  |  |  |  |  |

---

**Remarks:**
Exhibit 24 - Power of Attorney

**Signature:** /s/ Aaron Chan, Attorney-in-Fact  
**Date:** 2026-03-26

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**